Teva Pharmaceutical Industries EBITDA 2010-2023 | TEVA
Teva Pharmaceutical Industries annual and quarterly EBITDA history from 2010 to 2023. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Teva Pharmaceutical Industries EBITDA for the quarter ending December 31, 2023 was $0.988B, a 252.94% decline year-over-year.
- Teva Pharmaceutical Industries EBITDA for the twelve months ending December 31, 2023 was $1.586B, a 278.4% decline year-over-year.
- Teva Pharmaceutical Industries 2023 annual EBITDA was $1.586B, a 278.4% decline from 2022.
- Teva Pharmaceutical Industries 2022 annual EBITDA was $-0.889B, a 129.2% decline from 2021.
- Teva Pharmaceutical Industries 2021 annual EBITDA was $3.045B, a 251.19% decline from 2020.
Teva Pharmaceutical Industries Annual EBITDA
(Millions of US $) |
| 2023 |
$1,586 |
| 2022 |
$-889 |
| 2021 |
$3,045 |
| 2020 |
$-2,014 |
| 2019 |
$1,278 |
| 2018 |
$3,232 |
| 2017 |
$-15,372 |
| 2016 |
$3,678 |
| 2015 |
$4,660 |
| 2014 |
$6,109 |
| 2013 |
$4,079 |
| 2012 |
$5,172 |
| 2011 |
$4,608 |
| 2010 |
$4,848 |
| 2009 |
$3,313 |
Teva Pharmaceutical Industries Quarterly EBITDA
(Millions of US $) |
| 2023-12-31 |
$988 |
| 2023-09-30 |
$639 |
| 2023-06-30 |
$-346 |
| 2023-03-31 |
$305 |
| 2022-12-31 |
$-646 |
| 2022-09-30 |
$740 |
| 2022-06-30 |
$-592 |
| 2022-03-31 |
$-391 |
| 2021-12-31 |
$375 |
| 2021-09-30 |
$973 |
| 2021-06-30 |
$887 |
| 2021-03-31 |
$810 |
| 2020-12-31 |
$-3,827 |
| 2020-09-30 |
$667 |
| 2020-06-30 |
$554 |
| 2020-03-31 |
$592 |
| 2019-12-31 |
$564 |
| 2019-09-30 |
$331 |
| 2019-06-30 |
$-194 |
| 2019-03-31 |
$577 |
| 2018-12-31 |
$125 |
| 2018-09-30 |
$490 |
| 2018-06-30 |
$585 |
| 2018-03-31 |
$2,032 |
| 2017-12-31 |
$-12,489 |
| 2017-09-30 |
$905 |
| 2017-06-30 |
$-5,163 |
| 2017-03-31 |
$1,375 |
| 2016-12-31 |
$-226 |
| 2016-09-30 |
$932 |
| 2016-06-30 |
$1,383 |
| 2016-03-31 |
$1,589 |
| 2015-12-31 |
$298 |
| 2015-09-30 |
$1,709 |
| 2015-06-30 |
$1,270 |
| 2015-03-31 |
$1,383 |
| 2014-12-31 |
$1,597 |
| 2014-09-30 |
$1,637 |
| 2014-06-30 |
$1,442 |
| 2014-03-31 |
$1,433 |
| 2013-12-31 |
$1,456 |
| 2013-09-30 |
$1,386 |
| 2013-06-30 |
$-82 |
| 2013-03-31 |
$1,319 |
| 2012-12-31 |
$1,982 |
| 2012-09-30 |
$352 |
| 2012-06-30 |
$1,391 |
| 2012-03-31 |
$1,447 |
| 2011-12-31 |
$1,372 |
| 2011-09-30 |
$1,282 |
| 2011-06-30 |
$821 |
| 2011-03-31 |
$1,133 |
| 2010-12-31 |
$1,015 |
| 2010-09-30 |
$1,447 |
| 2010-06-30 |
$1,308 |
| 2010-03-31 |
$1,069 |
| 2009-12-31 |
$512 |
| 2009-09-30 |
$1,104 |
| 2009-06-30 |
$1,011 |
| 2009-03-31 |
$709 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$14.911B |
$15.846B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
